Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Narayanan D, Pozdnyakova O, Hasserjian RP, Patel SS, Weinberg OK. Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML. Blood Adv. 2021;5(11):2539-2549.

Shah RB, Cai Q, Aron M, Berney DM, Cheville JC, Deng F-, et al. Diagnosis of "cribriform" prostatic adenocarcinoma: an interobserver reproducibility study among urologic pathologists with recommendations. Am J Cancer Res. 2021;11(8):3990-4001.

Huang J, Salinas T, Westblade LF, Lee JR. The Potential Role of the Gut Microbiota in Kidney Transplantation. Kidney360. 2021;2(5):890-893.

Labrecque MP, Brown LG, Coleman IM, Lakely B, Brady NJ, Lee JK, et al. RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer. Cancer Res. 2021;81(18):4736-4750.

O'Leary MK, Chen SS, Westblade LF, Alabi CA. Design of a PEGylated Antimicrobial Prodrug with Species-Specific Activation. Biomacromolecules. 2021;22(2):984-992.

Ketas TJ, Chaturbhuj D, Cruz-Portillo VM, Francomano E, Golden E, Chandrasekhar S, et al. Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva. bioRxiv. 2021.

Iyengar NM, Zhou XK, Mendieta H, El-Hely O, Giri DD, Winston L, et al. Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations. NPJ Breast Cancer. 2021;7(1):18.

Shohdy KS, Bareja R, Sigouros M, Wilkes DC, Dorsaint P, Manohar J, et al. Functional comparison of exome capture-based methods for transcriptomic profiling of formalin-fixed paraffin-embedded tumors. NPJ Genom Med. 2021;6(1):66.

Manning DK, Shivdasani P, Koeller DR, Schwartz A, Rana HQ, Garber JE, et al. Assessment of genomic alterations in non-syndromic von Hippel-Lindau: Insight from integrating somatic and germline next generation sequencing genomic data. Data Brief. 2021;39:107653.

Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, et al. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828-2837.